Dishman Carbogen Amcis Ltd - 540701 - Board Meeting Intimation for Consideration Of Un-Audited Financial Result For The Third Quarter Ended 31St December, 2021
Dishman Carbogen Amcis Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/02/2022 ,inter alia, to consider and approve Un-Audited Financial Results of the Company for the third quarter ended on 31st December, 2021 Dishman Carbogen Amcis Ltd - 540701 - Shareholding for the Period Ended December 31, 2021
Dishman Carbogen Amcis Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2021. For more details, kindly Click here Dishman Carbogen Amcis Ltd - 540701 - Statement Of Investor Complaints For The Quarter Ended December 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0101 Name of the Signatory :- Shrima DaveDesignation :- Company Secretary and Compliance Officer Dishman Carbogen Amcis Ltd - 540701 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We submit herewith the confirmation certificate received from M/s. Link Intime India Private Limited, Registrar and Share Transfer Agent (RTA) as per regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31st December, 2021. Dishman Carbogen Amcis Ltd - 540701 - Closure of Trading Window
We would like to inform that as per Code of Conduct for prevention of Insider Trading adopted by the Company under SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, the Trading Window for dealing in securities/ shares of the Company shall remain closed with effect from 1st January, 2022 for all the Directors, Designated Persons and their immediate relative(s). The Trading Window will be opened 48 hours after the announcement of the Un-Audited Financial Results of the Company for the quarter ended 31st December, 2021. Dishman Carbogen Amcis Ltd - 540701 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform that successful results from the partnership with Boston University School of Medicine on Clinical Research Study that reveals positive response in vitamin D deficiency/insufficiency in patients with COVID-19. In this regard, please find enclosed herewith Press Release on the captioned subject. Q2FY22 Quarterly Result Announced for Dishman Carbogen Amcis Ltd.
Q2 & H1 FY22 RESULT HIGHLIGHTS: Net Revenue at Rs 4,589.0 mn in Q2 FY22 up by 4.4% YoY CRAMS revenue remained flat increasing by 0.3% YoY primarily due to: CRAMS India revenue increased by 560.7% due to resumption of servicing of CRAMS orders after clearances received from customers CRAMS - Switzerland, France & China revenue decreased by 11.8% due to deferment of supply of certain commercial products already produced to the next quarter according to the customer requirements. Marketable Molecules revenue increased 19.9% YoY primarily due to Carbogen Amcis BV revenue increased by 36.3% due to increase in demand for cholesterol and Vitamin D analogues globally. EBITDA Margin increased to 21.6% in Q2 FY22 due to: CRAMS India registering significant growth in the high margin CRAMS business. Carbogen Amcis AG maintaining healthy margins at 20% Carbogen Amcis UK margins increased due to supply of higher value intermediates and starting materials. Net Debt excluding lease liabilities was USD 101 mn as on September 30, 2021 (USD 101 mn as on June 30, 2021). Capital expenditure for H1 FY22 was approximately USD 31.85 mn, which majorly includes capex at Swiss and French sites. Result PDF Dishman Carbogen Amcis Ltd - 540701 - Announcement under Regulation 30 (LODR)-Investor Presentation
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, kindly find enclosed herewith Presentation on financial result for the quarter and half year ended 30th September, 2021 to be made to Analyst and Investors. The aforesaid presentation is also being hosted on the website of the Company, www.imdcal.com in accordance with the Regulation 46 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015. Dishman Carbogen Amcis Ltd - 540701 - UN-AUDITED FINANCIAL RESULTS AND STATUTORY AUDITORS' LIMITED REVIEW REPORT FOR THE QUARTER AND HALF YEAR ENDED 30/09/2021
As per Regulation 30 and 33 of SEBI (LODR) Regulations, 2015 we hereby inform that a Meeting of the Board of Directors of the Company was held today i.e. on Thursday, the 28th day of October, 2021 which was commenced at 1:00 P.M. and concluded at 02:55 P.M., inter alia, to consider and take on record the Un-audited Financial Results of the Company for the quarter and half year ended on 30th September, 2021 along with Statutory Auditors' Limited Review Report dated 28th day of October, 2021 issued by M/s. T R Chadha & Co. LLP, Chartered Accountants, in respect of the Un-audited Financial Results of the Company for the quarter and half year ended on 30th September, 2021, prepared in terms of Regulation 33 of SEBI (LODR) Regulations, 2015. At the said Board Meeting the said Un-audited Financial Results alongwith Limited Review Report were adopted and approved, which are attached herewith. Dishman Carbogen Amcis Ltd - 540701 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform that Company's wholly owned subsidiary namely CARBOGEN AMCIS SAS, France, announces the release of a new batch for clinical trials of AGuIX Drug Product for NH TherAguix, a clinical stage company developing innovative nanomedicine for the treatment of cancer In this regard, please find enclosed herewith Press Release on the captioned subject.